A combination assessment of LVEF and circulating biomarkers such as NT-proBNP and ST2/IL-33R may become useful for early detection of cardiac impairment in monitoring of breast cancer patients treated with trastuzumab, pertuzumab and docetaxel, enabling physicians to change or completely stop treatment when needed. This evidence concerns the gene IL1RL1 and breast cancer.